Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PDS Biotechnology Corporation (PDSB)
USD0.74
-0.01 (-1.00%)
US NASDAQ Healthcare Biotechnology
Address
25B Vreeland Road 7932
Princeton, NJ, US
Princeton, NJ, US
CEO
Frank K. Bedu-Addo
Website
pdsbiotech.com
IPO
2015-09-30
CIK 1472091 ISIN US70465T1079
Description
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Edge | EDGE | 2018-12-20 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.74
-0.01 (-1.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.56
Float Shares
51.57M
Free Float %
92.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.52% | +23.28% | +34.91% | +104.05% | +70.14% | +85.76% | +9.16% | -79.37% | -69.96% | -99.08% | -99.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (7 ratings, all time)
Buy
Price Targets & DCF
Current price
0.74
Low
9.00
+1,108.9%
Consensus
9.00
+1,108.9%
Median
9.00
+1,108.9%
High
9.00
+1,108.9%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
10.00
+1,243.2%
|
Quality scores
Altman Z-Score
-12.97
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+28.2% Q1'26: +38.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-0.6% ★ Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+27.2% Q1'26: +37.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-171.33× Q1'26: -0.20× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 366.7K (-100.0%)
|
11.25M
11.25M – 11.25M
+2,968.2% YoY
|
23.15M
23.15M – 23.15M
+105.8% YoY
|
3.80M
3.80M – 3.80M
-83.6% YoY
|
93.41M
93.41M – 93.41M
+2,358.1% YoY
|
196.92M
196.92M – 196.92M
+110.8% YoY
|
| EBITDA |
-33.75M
|
-30.30M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-33.81M
|
-30.33M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-37.61M
est: -41.98M (+10.4%)
|
-34.50M
est: -37.11M (+7.0%)
|
-24.53M
-29.27M – -19.79M
+33.9% YoY
|
-23.92M
-30.45M – -17.40M
+2.5% YoY
|
-21.95M
-28.22M – -15.68M
+8.2% YoY
|
23.19M
23.19M – 23.19M
+205.7% YoY
|
70.04M
70.04M – 70.04M
+202.0% YoY
|
| SGA |
13.70M
|
12.52M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-1.03
est: -1.11 (+7.2%)
|
-0.74
est: -0.80 (+7.5%)
|
-0.53
-0.63 – -0.43
+33.3% YoY
|
-0.52
-0.66 – -0.38
+2.5% YoY
|
-0.47
-0.61 – -0.34
+9.6% YoY
|
0.50
0.50 – 0.50
+206.4% YoY
|
1.51
1.51 – 1.51
+202.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
17
Total invested
1.75M
Insider transactions (90d)
0
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BARCLAYS GLOBAL INVESTORS, NA. | 3.09M | 3.15% | — | 2.07M | — | 2.07M | BK | Jersey Channel Islands | 2018-02-13 | ↗ |
| 2 | (. | 1.89M | 6.66% | 1.89M | — | 1.89M | — | IN | United States | 2021-06-21 | ↗ |
| 3 | (1) BlackRock, Inc. | 1.88M | 6.00% | 1.87M | — | 1.88M | — | HC | Delaware | 2024-01-29 | ↗ |
| 4 | of 6 Pages | 1.80M | 5.80% | 1.80M | — | 1.80M | — | IN | United States of America | 2017-04-25 | ↗ |
| 5 | 27-4413262 | 1.75M | 6.17% | 1.75M | — | 1.75M | — | OO | Maryland | 2021-06-21 | ↗ |
| 6 | NetScientific Plc | 1.05M | 7.21% | 1.05M | — | 1.05M | 11.00 | OO | — | 2020-03-02 | ↗ |
| 7 | E. Jeffrey Peierls1 | 1.01M | 6.95% | 142.6K | 865.7K | 142.6K | 865.7K | IN | United States | 2020-02-21 | ↗ |
| 8 | Melvin Lawson | 933.9K | 6.40% | 933.9K | — | 933.9K | 11.00 | IN | — | 2020-03-02 | ↗ |
| 9 | (“SM IX”) | 142.6K | 2.70% | 142.6K | — | 142.6K | 10.00 | OO | Delaware | 2019-03-28 | ↗ |
| 10 | (“SVP IX”) | 142.6K | 2.70% | 142.6K | — | 142.6K | — | PN | Delaware | 2019-03-28 | ↗ |
| 11 | Dr. Anand Mehra (“Mehra”) | 142.6K | 2.70% | — | 142.6K | — | 142.6K | IN | U.S. Citizen | 2019-03-28 | ↗ |
| 12 | Dr. James I. Healy (“Healy”) | 142.6K | 2.70% | — | 142.6K | — | 142.6K | IN | U.S. Citizen | 2019-03-28 | ↗ |
| 13 | Dr. Michael F. Powell (“Powell”) | 142.6K | 2.70% | — | 142.6K | — | 142.6K | IN | U.S. Citizen | 2019-03-28 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
17
-25 vs prev Q
New positions
4
Closed positions
29
Increased
8
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 2.83M +2.8M (+100.0%) | 2.18M +2.2M (+100.0%) | 6.05% +6.048 pp | 0.03% +0.026 pp | USD0.77 +0.0% | 4 qtrs — |
| 2 | VANGUARD GROUP INC | 1.95M +49.5K (+2.6%) | 1.50M -418.2K (-21.8%) | 4.16% +0.020 pp | 0.00% +0.000 pp | USD3.71 -79.2% | 28 qtrs — |
| 3 | BLACKROCK, INC. | 522.2K +4.7K (+0.9%) | 402.0K -120.7K (-23.1%) | 1.11% -0.013 pp | 0.00% +0.000 pp | USD3.51 -78.1% | 6 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 520.4K +38.4K (+8.0%) | 400.7K -86.2K (-17.7%) | 1.11% +0.060 pp | 0.00% +0.000 pp | USD3.98 -80.7% | 28 qtrs — |
| 5 | UBS GROUP AG | 251.7K +51.5K (+25.7%) | 193.8K -8.4K (-4.2%) | 0.54% +0.101 pp | 0.00% +0.000 pp | USD1.27 -39.4% | 18 qtrs — |
| 6 | BLAIR WILLIAM & CO/IL | 250.0K +— (+0.0%) | 192.5K -60.1K (-23.8%) | 0.53% -0.011 pp | 0.00% 0.000 pp | USD2.28 -66.2% | 8 qtrs — |
| 7 | COMMONWEALTH EQUITY SERVICES, LLC | 196.8K +106.3K (+117.5%) | 151.5K +60.5K (+66.5%) | 0.42% +0.223 pp | 0.00% +0.000 pp | USD2.06 -62.6% | 8 qtrs — |
| 8 | SQUAREPOINT OPS LLC | 192.6K -99.1K (-34.0%) | 148.2K -146.3K (-49.7%) | 0.41% -0.225 pp | 0.00% 0.000 pp | USD1.12 -31.3% | 3 qtrs — |
| 9 | INSPIRION WEALTH ADVISORS, LLC | 180.5K -163.9K (-47.6%) | 138.9K -1.2M (-89.4%) | 0.39% -0.365 pp | 0.02% -0.167 pp | USD1.54 -50.0% | 27 qtrs — |
| 10 | RENAISSANCE TECHNOLOGIES LLC | 176.7K -99.2K (-35.9%) | 136.0K -142.6K (-51.2%) | 0.38% -0.224 pp | 0.00% 0.000 pp | USD1.13 -31.9% | 28 qtrs — |
| 11 | NORTHERN TRUST CORP | 143.9K +30.4K (+26.8%) | 110.8K -3.9K (-3.4%) | 0.31% +0.060 pp | 0.00% +0.000 pp | USD3.06 -74.8% | 24 qtrs — |
| 12 | STATE STREET CORP | 133.3K +— (+0.0%) | 102.6K -32.0K (-23.8%) | 0.28% -0.006 pp | 0.00% +0.000 pp | USD5.42 -85.8% | 19 qtrs — |
| 13 | AMUSSEN HUNSAKER ASSOCIATES LLC | 75.0K +— (+0.0%) | 57.7K -18.8K (-24.5%) | 0.16% -0.003 pp | 0.01% -0.002 pp | USD1.01 -23.8% | 14 qtrs — |
| 14 | BANK OF NEW YORK MELLON CORP | 69.3K +40.0K (+136.6%) | 53.4K +23.8K (+80.3%) | 0.15% +0.084 pp | 0.00% +0.000 pp | USD2.83 -72.8% | 24 qtrs — |
| 15 | TEMPUS WEALTH PLANNING, LLC | 61.8K +14.0K (+29.3%) | 47.6K -704.0 (-1.5%) | 0.13% +0.028 pp | 0.01% 0.000 pp | USD1.72 -55.2% | 7 qtrs — |
| 16 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38.6K -55.8K (-59.1%) | 29.7K -65.6K (-68.8%) | 0.08% -0.123 pp | 0.00% +0.000 pp | USD1.59 -51.6% | 19 qtrs — |
| 17 | XTX TOPCO LTD | 34.2K +14.5K (+73.7%) | 26.3K +6.4K (+32.4%) | 0.07% +0.030 pp | 0.00% 0.000 pp | USD0.91 -15.4% | 2 qtrs — |
| 18 | VIRTU FINANCIAL LLC | 32.1K +32.1K (+100.0%) | 25.0K +25.0K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.001 pp | USD0.77 +0.0% | 5 qtrs — |
| 19 | ACT CAPITAL MANAGEMENT, LLC | 30.0K +30.0K (+100.0%) | 23.1K +23.1K (+100.0%) | 0.06% +0.064 pp | 0.02% +0.019 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 20 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 25.7K -8.8K (-25.5%) | 19.8K -15.1K (-43.2%) | 0.05% -0.020 pp | 0.00% +0.000 pp | USD1.01 -23.8% | 2 qtrs — |
| 21 | SIMPLEX TRADING, LLC | 19.1K +6.7K (+54.0%) | 14.7K +2.7K (+22.6%) | 0.04% +0.014 pp | 0.00% +0.000 pp | USD0.93 -17.2% | 19 qtrs — |
| 22 | STONEX GROUP INC. | 16.0K +16.0K (+100.0%) | 12.3K +12.3K (+100.0%) | 0.03% +0.034 pp | 0.00% +0.001 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 23 | FIRST MANHATTAN CO. LLC. | 15.0K +— (+0.0%) | 11.5K -3.6K (-23.8%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.19 -35.3% | 4 qtrs — |
| 24 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | 14.8K -4.0K (-21.3%) | 11.4K -7.6K (-40.0%) | 0.03% -0.009 pp | 0.00% +0.000 pp | USD2.91 -73.5% | 9 qtrs — |
| 25 | GROUND SWELL CAPITAL, LLC | 14.7K +14.7K (+100.0%) | 11.3K +11.3K (+100.0%) | 0.03% +0.031 pp | 0.02% +0.023 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 26 | RAYMOND JAMES FINANCIAL INC | 13.7K -40.0 (-0.3%) | 10.6K -3.3K (-24.0%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD1.63 -52.8% | 5 qtrs — |
| 27 | WEALTH GROUP, LTD. | 13.4K +13.4K (+100.0%) | 10.0K +10.0K (+100.0%) | 0.03% +0.029 pp | 0.01% +0.010 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 28 | DAVENPORT & CO LLC | 10.0K +10.0K (+100.0%) | 7.7K +7.7K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 29 | GRANDFIELD & DODD, LLC | 10.0K +— (+0.0%) | 7.7K -2.4K (-23.8%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD1.33 -42.1% | 3 qtrs — |
| 30 | CITIGROUP INC | 9.4K +9.4K (+39,037.5%) | 7.2K +7.2K (+30,029.2%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD0.77 +0.0% | 2 qtrs — |
| 31 | WELLS FARGO & COMPANY/MN | 5.3K +— (+0.0%) | 4.1K -1.3K (-23.8%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD3.88 -80.2% | 20 qtrs — |
| 32 | MORGAN STANLEY | 4.9K -3.3K (-40.4%) | 3.8K -4.6K (-54.6%) | 0.01% -0.008 pp | 0.00% +0.000 pp | USD10.09 -92.4% | 22 qtrs — |
| 33 | GROUP ONE TRADING, L.P. | 3.9K +3.9K (+100.0%) | 3.0K +3.0K (+100.0%) | 0.01% +0.008 pp | 0.00% +0.000 pp | USD0.77 +0.0% | 1 qtrs NEW |
| 34 | CREATIVE FINANCIAL DESIGNS INC /ADV | 3.0K +— (+0.0%) | 2.3K -721.0 (-23.8%) | 0.01% 0.000 pp | 0.00% 0.000 pp | USD2.59 -70.3% | 7 qtrs — |
| 35 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.2K +2.2K (+100.0%) | 1.7K +1.7K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD0.77 +0.0% | 22 qtrs — |
| 36 | JONES FINANCIAL COMPANIES LLLP | 2.0K +— (+0.0%) | 1.5K -502.0 (-24.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.01 -23.8% | 2 qtrs — |
| 37 | BANK OF AMERICA CORP /DE/ | 1.0K -9.0 (-0.9%) | 791.00 -257.0 (-24.5%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.75 -79.5% | 19 qtrs — |
| 38 | TRUVESTMENTS CAPITAL LLC | 655.00 +— (+0.0%) | 504.00 -158.0 (-23.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.82 -79.8% | 20 qtrs — |
| 39 | BNP PARIBAS ARBITRAGE, SNC | 648.00 -488.0 (-43.0%) | 499.00 -648.0 (-56.5%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD5.00 -84.6% | 13 qtrs — |
| 40 | SBI SECURITIES CO., LTD. | 109.00 -1.0 (-0.9%) | 84.00 -27.0 (-24.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.47 -47.6% | 5 qtrs — |
| 41 | JPMORGAN CHASE & CO | 19.00 -600.0 (-96.9%) | 15.00 -610.0 (-97.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD5.00 -84.6% | 11 qtrs — |
| 42 | ADVISOR GROUP HOLDINGS, INC. | 17.00 +— (+0.0%) | 13.00 -4.0 (-23.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.88 -80.2% | 22 qtrs — |
| 43 | JANE STREET GROUP, LLC | — -36.6K (-100.0%) | — -36.9K (-100.0%) | 0.00% -0.080 pp | 0.00% +0.000 pp | USD— | 14 qtrs SOLD |
| 44 | BAADER BANK AKTIENGESELLSCHAFT | — -10.5K (-100.0%) | — -6.6K (-100.0%) | 0.00% -0.023 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 45 | BURNS J W & CO INC/NY | — -10.3K (-100.0%) | — -10.4K (-100.0%) | 0.00% -0.022 pp | 0.00% -0.001 pp | USD— | 5 qtrs SOLD |
| 46 | CAPTION MANAGEMENT, LLC | — -219.0K (-100.0%) | — -221.2K (-100.0%) | 0.00% -0.477 pp | 0.00% -0.002 pp | USD— | 7 qtrs SOLD |
| 47 | CITADEL ADVISORS LLC | — -28.4K (-100.0%) | — -28.7K (-100.0%) | 0.00% -0.062 pp | 0.00% +0.000 pp | USD— | 19 qtrs SOLD |
| 48 | DIMENSIONAL FUND ADVISORS LP | — -18.4K (-100.0%) | — -18.6K (-100.0%) | 0.00% -0.040 pp | 0.00% +0.000 pp | USD— | 17 qtrs SOLD |
| 49 | FMR LLC | — -1.0K (-100.0%) | — -1.0K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 13 qtrs SOLD |
| 50 | ACADIAN ASSET MANAGEMENT LLC | — -61.8K (-100.0%) | — -61.0K (-100.0%) | 0.00% -0.135 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 51 | MERCER GLOBAL ADVISORS INC /ADV | — -12.5K (-100.0%) | — -12.6K (-100.0%) | 0.00% -0.027 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
| 52 | RIALTO WEALTH MANAGEMENT, LLC | — -400.0 (-100.0%) | — -404.0 (-100.0%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 53 | ROYAL BANK OF CANADA | — -1.9K (-100.0%) | — -2.0K (-100.0%) | 0.00% -0.004 pp | 0.00% +0.000 pp | USD— | 17 qtrs SOLD |
| 54 | STRATOS WEALTH PARTNERS, LTD. | — -11.3K (-100.0%) | — -11.4K (-100.0%) | 0.00% -0.025 pp | 0.00% 0.000 pp | USD— | 3 qtrs SOLD |
| 55 | TWO SIGMA SECURITIES, LLC | — -14.1K (-100.0%) | — -14.3K (-100.0%) | 0.00% -0.031 pp | 0.00% -0.002 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 147.0K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 616.4K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 2.3K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 6.3K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 462.08 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.07M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.3K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.3K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 515.12 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 56.78 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
5
Sells
0
Shares acquired
113.5K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+113,500
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-12 | Toutain Stephan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 0.98 | 294.0K | 300,000 | D | ↗ |
| 2026-01-12 | Shepard Kirk V. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 0.98 | 294.0K | 300,000 | D | ↗ |
| 2026-01-12 | Iliev Ilian | Director | A-Award | A | Employee Stock Option (Right to Buy) | 54,876 | 0.98 | 53.8K | 54,876 | D | ↗ |
| 2026-01-12 | Glover Stephen C. | Director | A-Award | A | Employee Stock Option (Right to Buy) | 54,876 | 0.98 | 53.8K | 54,876 | D | ↗ |
| 2026-01-12 | Freitag Gregory Gene | Director | A-Award | A | Employee Stock Option (Right to Buy) | 54,876 | 0.98 | 53.8K | 54,876 | D | ↗ |
| 2026-01-12 | CONN GREGORY | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 0.98 | 147.0K | 150,000 | D | ↗ |
| 2026-01-12 | Brown Spencer D. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 0.98 | 294.0K | 300,000 | D | ↗ |
| 2026-01-12 | Boesgaard Lars | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 0.98 | 294.0K | 300,000 | D | ↗ |
| 2026-01-12 | BRAWLEY OTIS W | Director | A-Award | A | Employee Stock Option (Right to Buy) | 54,876 | 0.98 | 53.8K | 54,876 | D | ↗ |
| 2026-01-12 | BEDU-ADDO FRANK | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 548,782 | 0.98 | 537.8K | 548,782 | D | ↗ |
| 2026-01-12 | Ali-Jackson Kamil | Director | A-Award | A | Employee Stock Option (Right to Buy) | 54,876 | 0.98 | 53.8K | 54,876 | D | ↗ |
| 2025-06-12 | Toutain Stephan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.79 | 268.5K | 150,000 | D | ↗ |
| 2025-06-12 | Shepard Kirk V. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.79 | 268.5K | 150,000 | D | ↗ |
| 2025-06-12 | CONN GREGORY | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 1.79 | 71.6K | 40,000 | D | ↗ |
| 2025-06-12 | Brown Spencer D. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.79 | 268.5K | 150,000 | D | ↗ |
| 2025-06-12 | Boesgaard Lars | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.79 | 268.5K | 150,000 | D | ↗ |
| 2025-06-12 | BEDU-ADDO FRANK | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 1.79 | 268.5K | 150,000 | D | ↗ |
| 2025-06-11 | Iliev Ilian | Director | A-Award | A | Employee Stock Option (Right to Buy) | 22,700 | 1.75 | 39.7K | 22,700 | D | ↗ |
| 2025-06-11 | Glover Stephen C. | Director | A-Award | A | Employee Stock Option (Right to Buy) | 22,700 | 1.75 | 39.7K | 22,700 | D | ↗ |
| 2025-06-11 | Freitag Gregory Gene | Director | A-Award | A | Employee Stock Option (Right to Buy) | 22,700 | 1.75 | 39.7K | 22,700 | D | ↗ |
| 2025-06-11 | BRAWLEY OTIS W | Director | A-Award | A | Employee Stock Option (Right to Buy) | 22,700 | 1.75 | 39.7K | 22,700 | D | ↗ |
| 2025-06-11 | Ali-Jackson Kamil | Director | A-Award | A | Employee Stock Option (Right to Buy) | 22,700 | 1.75 | 39.7K | 22,700 | D | ↗ |
| 2025-02-28 | Glover Stephen C. | Director | P-Purchase | A | Common Stock | 15,061 | 1.66 | 25.0K | 78,851 | D | ↗ |
| 2025-02-28 | Freitag Gregory Gene | Director | P-Purchase | A | Common Warrant | 15,060 | 1.53 | 23.0K | 15,060 | D | ↗ |
| 2024-06-24 | SYKES RICHARD | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 2.86 | 25.7K | 9,000 | — | ↗ |
| 2024-06-24 | Iliev Ilian | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 2.86 | 25.7K | 9,000 | — | ↗ |
| 2024-06-24 | Glover Stephen C. | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 2.86 | 25.7K | 9,000 | — | ↗ |
| 2024-06-24 | Freitag Gregory Gene | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 2.86 | 25.7K | 9,000 | — | ↗ |
| 2024-06-24 | BRAWLEY OTIS W | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 2.86 | 25.7K | 9,000 | — | ↗ |
| 2024-06-24 | Ali-Jackson Kamil | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 2.86 | 25.7K | 9,000 | — | ↗ |
| 2024-05-01 | Toutain Stephan | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-28 | CONN GREGORY | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 46,648 | 5.87 | 273.8K | 46,648 | D | ↗ |
| 2024-02-28 | Brown Spencer D. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 56,000 | 5.87 | 328.7K | 56,000 | D | ↗ |
| 2024-02-28 | BEDU-ADDO FRANK | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 300,000 | 5.87 | 1.76M | 300,000 | D | ↗ |
| 2024-01-22 | Shepard Kirk V. | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 4.49 | 898.0K | 200,000 | — | ↗ |
| 2023-12-04 | Boesgaard Lars | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 5.28 | 1.06M | 200,000 | — | ↗ |
| 2023-07-14 | SYKES RICHARD | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 5.13 | 46.2K | 9,000 | — | ↗ |
| 2023-07-14 | Iliev Ilian | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 5.13 | 46.2K | 9,000 | — | ↗ |
| 2023-07-14 | Glover Stephen C. | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 5.13 | 46.2K | 9,000 | — | ↗ |
| 2023-07-14 | Freitag Gregory Gene | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 5.13 | 46.2K | 9,000 | — | ↗ |
| 2023-07-14 | BRAWLEY OTIS W | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 5.13 | 46.2K | 9,000 | — | ↗ |
| 2023-07-14 | Ali-Jackson Kamil | Director | A-Award | A | Employee Stock Option (Right to Buy) | 9,000 | 5.13 | 46.2K | 9,000 | — | ↗ |
| 2023-01-05 | WOOD LAUREN | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 110,800 | 0.00 | — | 110,800 | — | ↗ |
| 2023-01-05 | HILL MATTHEW C | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 161,200 | 0.00 | — | 161,200 | — | ↗ |
| 2023-01-05 | CONN GREGORY | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 137,200 | 0.00 | — | 137,200 | — | ↗ |
| 2023-01-05 | Brown Spencer D. | Director | A-Award | A | Employee Stock Option (Right to Buy) | 20,400 | 0.00 | — | 20,400 | — | ↗ |
| 2023-01-05 | BEDU-ADDO FRANK | Director | A-Award | A | Employee Stock Option (Right to Buy) | 385,300 | 0.00 | — | 385,300 | — | ↗ |
| 2022-12-02 | BEDU-ADDO FRANK | Director | F-InKind | D | Common Stock | 175,184 | 9.78 | 1.71M | 690,866 | — | ↗ |
| 2022-06-28 | SYKES RICHARD | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 3.90 | 35.1K | 9,000 | — | ↗ |
| 2022-06-28 | Iliev Ilian | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 3.90 | 35.1K | 9,000 | — | ↗ |
| 2022-06-28 | Glover Steve C | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 3.90 | 35.1K | 9,000 | — | ↗ |
| 2022-06-28 | Freitag Gregory Gene | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 3.90 | 35.1K | 9,000 | — | ↗ |
| 2022-06-28 | BRAWLEY OTIS W | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2022-06-28 | Ali-Jackson Kamil | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2022-06-02 | Brown Spencer D. | Director | A-Award | A | Employee Stock Option (Right to Buy) | 150,000 | 0.00 | — | 150,000 | — | ↗ |
| 2022-06-01 | Brown Spencer D. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-19 | WOOD LAUREN | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 88,600 | 6.28 | 556.4K | 88,600 | — | ↗ |
| 2022-01-19 | CONN GREGORY | — | A-Award | A | Employee Stock Option (Right to Buy) | 112,100 | 6.28 | 704.0K | 112,100 | — | ↗ |
| 2022-01-19 | BEDU-ADDO FRANK | — | A-Award | D | Stock Option (Right to Buy) | 291,500 | 6.28 | 1.83M | 291,500 | — | ↗ |
| 2021-12-13 | HILL MATTHEW C | — | P-Purchase | A | Common Stock | 100 | 9.00 | 900.00 | 4,075 | — | ↗ |
| 2021-10-19 | HILL MATTHEW C | — | A-Award | A | Stock Option (Right to Buy) | 202,800 | 12.03 | 2.44M | 202,800 | — | ↗ |
| 2021-10-18 | HILL MATTHEW C | — | — | D | Common Stock | 0 | 0.00 | — | 975 | — | ↗ |
| 2021-09-30 | Trochimiuk Janetta | — | — | D | Stock Option (Right to Buy) | 10,000 | 2.88 | 28.8K | 0 | — | ↗ |
| 2021-06-17 | SYKES RICHARD | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 9.95 | 89.6K | 9,000 | — | ↗ |
| 2021-06-17 | Iliev Ilian | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 9.95 | 89.6K | 9,000 | — | ↗ |
| 2021-06-17 | Glover Steve C | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 9.95 | 89.6K | 9,000 | — | ↗ |
| 2021-06-17 | Freitag Gregory Gene | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 9.95 | 89.6K | 9,000 | — | ↗ |
| 2021-06-17 | BRAWLEY OTIS W | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 9.95 | 89.6K | 9,000 | — | ↗ |
| 2021-06-17 | Ali-Jackson Kamil | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 9.95 | 89.6K | 9,000 | — | ↗ |
| 2021-06-16 | Bloomquist DeLyle W | — | M-Exempt | A | Common Stock | 2,970 | 5.99 | 17.8K | 183,888 | — | ↗ |
| 2021-06-15 | VAN VOORHEES SETH | — | P-Purchase | A | Common Stock | 17,647 | 8.50 | 150.0K | 17,647 | — | ↗ |
| 2021-06-15 | Glover Steve C | — | P-Purchase | A | Common Stock | 5,882 | 8.50 | 50.0K | 63,790 | — | ↗ |
| 2021-06-15 | Freitag Gregory Gene | — | P-Purchase | A | Common Stock | 5,882 | 8.50 | 50.0K | 46,153 | — | ↗ |
| 2021-06-15 | BEDU-ADDO FRANK | — | M-Exempt | D | Stock Option (Right to Buy) | 53,174 | 6.57 | 349.4K | 0 | — | ↗ |
| 2021-06-15 | Ali-Jackson Kamil | — | P-Purchase | A | Common Stock | 11,764 | 8.50 | 100.0K | 11,764 | — | ↗ |
| 2021-01-04 | VAN VOORHEES SETH | — | A-Award | A | Stock Option (Right to Buy) | 202,800 | 2.28 | 462.4K | 202,800 | — | ↗ |
| 2021-01-01 | VAN VOORHEES SETH | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-08 | WOOD LAUREN | — | A-Award | A | Stock Option (Right to Buy) | 210,500 | 2.43 | 511.5K | 210,500 | — | ↗ |
| 2020-12-08 | King Michael N. | — | A-Award | A | Stock Option (Right to Buy) | 50,000 | 2.43 | 121.5K | 50,000 | — | ↗ |
| 2020-12-08 | CONN GREGORY | — | A-Award | A | Stock Option (Right to Buy) | 122,400 | 2.43 | 297.4K | 122,400 | — | ↗ |
| 2020-12-08 | BEDU-ADDO FRANK | — | A-Award | A | Stock Option (Right to Buy) | 707,800 | 2.43 | 1.72M | 707,800 | — | ↗ |
| 2020-11-03 | BRAWLEY OTIS W | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 2.09 | 18.8K | 9,000 | — | ↗ |
| 2020-06-23 | WOOD LAUREN | — | A-Award | A | Employee Stock Option (Right to Buy) | 35,000 | 1.45 | 50.8K | 35,000 | — | ↗ |
| 2020-06-23 | SYKES RICHARD | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 1.45 | 13.1K | 9,000 | — | ↗ |
| 2020-06-23 | Iliev Ilian | — | A-Award | A | Stock Option (Right to Buy) | 1,874 | 1.45 | 2.7K | 1,874 | — | ↗ |
| 2020-06-23 | Glover Steve C | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 1.45 | 13.1K | 9,000 | — | ↗ |
| 2020-06-23 | Freitag Gregory Gene | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 1.45 | 13.1K | 9,000 | — | ↗ |
| 2020-06-23 | CONN GREGORY | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 35,000 | 1.45 | 50.8K | 35,000 | — | ↗ |
| 2020-06-23 | Bloomquist DeLyle W | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 1.45 | 13.1K | 9,000 | — | ↗ |
| 2020-06-23 | BEDU-ADDO FRANK | — | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 1.45 | 181.3K | 125,000 | — | ↗ |
| 2020-06-23 | Ali-Jackson Kamil | — | A-Award | A | Stock Option (Right to Buy) | 3,033 | 1.45 | 4.4K | 3,033 | — | ↗ |
| 2020-04-08 | Iliev Ilian | — | A-Award | A | Stock Option (Right to Buy) | 4,500 | 0.72 | 3.2K | 4,500 | — | ↗ |
| 2020-03-23 | Trochimiuk Janetta | — | — | D | Stock Option (Right to Buy) | 10,000 | 2.88 | 28.8K | 0 | — | ↗ |
| 2020-02-21 | Ali-Jackson Kamil | — | A-Award | A | Stock Option (Right to Buy) | 9,000 | 1.31 | 11.8K | 9,000 | — | ↗ |
| 2020-02-14 | Saik Andrew | — | A-Award | A | Common Stock | 38,400 | 1.30 | 49.9K | 42,549 | — | ↗ |
| 2020-02-14 | SYKES RICHARD | — | A-Award | A | Common Stock | 384,615 | 1.30 | 500.0K | 445,108 | — | ↗ |
| 2020-02-14 | Glover Steve C | — | A-Award | A | Common Stock | 38,400 | 1.30 | 49.9K | 57,908 | — | ↗ |
| 2020-02-14 | Freitag Gregory Gene | — | A-Award | A | Common Stock | 38,400 | 1.30 | 49.9K | 40,271 | — | ↗ |
| 2019-06-28 | SYKES RICHARD | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 5.99 | 53.9K | 9,000 | — | ↗ |
| 2019-06-28 | LOUGHLIN JAMES J | Director | A-Award | A | Stock Option (Right To Purchase) | 9,000 | 5.99 | 53.9K | 9,000 | — | ↗ |
| 2019-06-28 | Glover Steve C | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 5.99 | 53.9K | 9,000 | — | ↗ |
| 2019-06-28 | Freitag Gregory Gene | Director | A-Award | A | Stock Option (Right to Buy) | 9,000 | 5.99 | 53.9K | 9,000 | — | ↗ |
| 2019-06-28 | Bloomquist DeLyle W | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 9,000 | 5.99 | 53.9K | 9,000 | — | ↗ |
| 2019-06-28 | BEDU-ADDO FRANK | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 5.99 | 599.0K | 100,000 | — | ↗ |
| 2019-06-06 | WOOD LAUREN | Officer | A-Award | A | Stock Option (Right To Purchase) | 62,715 | 6.39 | 400.7K | 62,715 | — | ↗ |
| 2019-06-06 | Saik Andrew | Director / Officer | A-Award | A | Stock Option (Right To Purchase) | 62,715 | 6.39 | 400.7K | 62,715 | — | ↗ |
| 2019-06-06 | CONN GREGORY | Officer | A-Award | A | Stock Option (Right To Purchase) | 40,000 | 6.39 | 255.6K | 40,000 | — | ↗ |
| 2019-04-02 | Glover Steve C | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-15 | WOOD LAUREN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-03-15 | Spiegel Robert J. | Director | M-Exempt | D | Restricted Stock Units | 10,000 | 0.00 | — | 0 | — | ↗ |
| 2019-03-15 | Saik Andrew | Officer | M-Exempt | A | Common Stock | 82,999 | 0.00 | — | 82,999 | — | ↗ |
| 2019-03-15 | SYKES RICHARD | — | — | D | Common Stock | 0 | 0.00 | — | 60,493 | — | ↗ |
| 2019-03-15 | Ratcliffe Liam | Director | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2019-03-15 | Macdonald R. Loch | Director | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 580,602 | — | ↗ |
| 2019-03-15 | MIDDLEKAUFF W BRADFORD | Officer | M-Exempt | A | Common Stock | 49,766 | 0.00 | — | 59,766 | — | ↗ |
| 2019-03-15 | Leuthner Brian A | Director / Officer | M-Exempt | A | Common Stock | 169,032 | 0.00 | — | 239,268 | — | ↗ |
| 2019-03-15 | LOUGHLIN JAMES J | Director | M-Exempt | D | Restricted Stock Units | 10,000 | 0.00 | — | 0 | — | ↗ |
| 2019-03-15 | King Michael N. | Director | — | D | Employee Stock Option (Right to Buy) | 52,934 | 6.87 | 363.7K | 0 | — | ↗ |
| 2019-03-15 | Freitag Gregory Gene | — | — | D | Stock Option (Right to Buy) | 11,218 | 9.04 | 101.4K | 0 | — | ↗ |
| 2019-03-15 | Crane Rosemary A | Director | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2019-03-15 | CONN GREGORY | — | — | D | Employee Stock Option (Right to Buy) | 14,450 | 15.33 | 221.5K | 0 | — | ↗ |
| 2019-03-15 | Bloomquist DeLyle W | — | — | I | Common Stock | 0 | 0.00 | — | 605,023 | — | ↗ |
| 2019-03-15 | BLECH ISAAC | Director | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2019-03-15 | BEDU-ADDO FRANK | — | — | D | Employee Stock Option (Right to Buy) | 17,724 | 4.69 | 83.1K | 0 | — | ↗ |
| 2019-03-15 | BARER SOL J | Director | M-Exempt | A | Common Stock | 20,000 | 0.00 | — | 678,075 | — | ↗ |
| 2019-03-14 | King Michael N. | Director | — | D | Employee Stock Option (Right to Buy) | 44,871 | 9.04 | 405.6K | 0 | — | ↗ |
| 2018-08-15 | Wyant Alyssa | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-08-14 | Wyant Alyssa | Officer | A-Award | A | Restricted Stock Units | 49,766 | 0.00 | — | 49,766 | — | ↗ |
| 2018-08-14 | Spiegel Robert J. | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-14 | Saik Andrew | Officer | A-Award | A | Restricted Stock Units | 82,999 | 0.00 | — | 82,999 | — | ↗ |
| 2018-08-14 | Ratcliffe Liam | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-14 | Macdonald R. Loch | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-14 | MIDDLEKAUFF W BRADFORD | Officer | A-Award | A | Restricted Stock Units | 49,766 | 0.00 | — | 49,766 | — | ↗ |
| 2018-08-14 | MARCHIO ALBERT N II | Officer | A-Award | A | Restricted Stock Units | 41,666 | 0.00 | — | 41,666 | — | ↗ |
| 2018-08-14 | Leuthner Brian A | Director / Officer | A-Award | A | Restricted Stock Units | 169,032 | 0.00 | — | 169,032 | — | ↗ |
| 2018-08-14 | LOUGHLIN JAMES J | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-14 | Faleck Herbert J | Officer | A-Award | A | Restricted Stock Units | 59,833 | 0.00 | — | 59,833 | — | ↗ |
| 2018-08-14 | Crane Rosemary A | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-14 | BLECH ISAAC | Director | A-Award | A | Restricted Stock Units | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2018-08-14 | BARER SOL J | Director | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2018-06-19 | Wyant Alyssa | Officer | A-Award | A | Stock Option (Right To Purchase) | 99,534 | 1.10 | 109.5K | 99,534 | — | ↗ |
| 2018-06-19 | Spiegel Robert J. | Director | A-Award | A | Stock Option (Right To Purchase) | 20,000 | 1.10 | 22.0K | 20,000 | — | ↗ |
| 2018-06-19 | Saik Andrew | Officer | A-Award | A | Stock Option (Right To Purchase) | 166,001 | 1.10 | 182.6K | 166,001 | — | ↗ |
| 2018-06-19 | Ratcliffe Liam | Director | A-Award | A | Stock Option (Right To Purchase) | 20,000 | 1.10 | 22.0K | 20,000 | — | ↗ |
| 2018-06-19 | Macdonald R. Loch | Director | A-Award | A | Stock Option (Right To Purchase) | 20,000 | 1.10 | 22.0K | 20,000 | — | ↗ |
| 2018-06-19 | MIDDLEKAUFF W BRADFORD | Officer | A-Award | A | Stock Option (Right To Purchase) | 99,534 | 1.10 | 109.5K | 99,534 | — | ↗ |
| 2018-06-19 | MARCHIO ALBERT N II | Officer | A-Award | A | Stock Option (Right To Purchase) | 83,334 | 1.10 | 91.7K | 83,334 | — | ↗ |
| 2018-06-19 | Leuthner Brian A | Director / Officer | A-Award | A | Stock Option (Right To Purchase) | 338,068 | 1.10 | 371.9K | 338,068 | — | ↗ |
| 2018-06-19 | LOUGHLIN JAMES J | Director | A-Award | A | Stock Option (Right To Purchase) | 20,000 | 1.10 | 22.0K | 20,000 | — | ↗ |
| 2018-06-19 | Faleck Herbert J | Officer | A-Award | A | Stock Option (Right To Purchase) | 119,667 | 1.10 | 131.6K | 119,667 | — | ↗ |
| 2018-06-19 | Crane Rosemary A | Director | A-Award | A | Stock Option (Right To Purchase) | 20,000 | 1.10 | 22.0K | 20,000 | — | ↗ |
| 2018-06-19 | BLECH ISAAC | Director | A-Award | A | Stock Option (Right To Purchase) | 20,000 | 1.10 | 22.0K | 20,000 | — | ↗ |
| 2018-06-19 | BARER SOL J | Director | A-Award | A | Stock Option (Right To Purchase) | 40,000 | 1.10 | 44.0K | 40,000 | — | ↗ |
| 2018-03-23 | Conti Kurt G | Director | J-Other | D | Common Stock | 58,476 | 0.00 | — | 0 | — | ↗ |
| 2018-03-22 | Macdonald R. Loch | Director / Officer | S-Sale | D | Common Stock | 2,500 | 16.41 | 41.0K | 570,602 | — | ↗ |
| 2018-03-21 | Macdonald R. Loch | Director / Officer | S-Sale | D | Common Stock | 2,500 | 16.52 | 41.3K | 573,102 | — | ↗ |
| 2018-03-20 | Macdonald R. Loch | Director / Officer | S-Sale | D | Common Stock | 5,000 | 16.47 | 82.4K | 575,602 | — | ↗ |
| 2018-03-19 | Macdonald R. Loch | Director / Officer | S-Sale | D | Common Stock | 2,500 | 16.66 | 41.7K | 580,602 | — | ↗ |
| 2018-03-05 | Leuthner Brian A | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-03-02 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 15.08 | 37.7K | 70,236 | — | ↗ |
| 2018-03-01 | Wyant Alyssa | Officer | A-Award | A | Stock Option (Right To Purchase) | 50,000 | 14.98 | 749.0K | 50,000 | — | ↗ |
| 2018-03-01 | Saik Andrew | Officer | A-Award | A | Stock Option (Right To Purchase) | 50,000 | 14.98 | 749.0K | 50,000 | — | ↗ |
| 2018-03-01 | MIDDLEKAUFF W BRADFORD | Officer | A-Award | A | Stock Option (Right To Purchase) | 65,000 | 14.98 | 973.7K | 65,000 | — | ↗ |
| 2018-03-01 | MARCHIO ALBERT N II | Officer | A-Award | A | Stock Option (Right To Purchase) | 25,000 | 14.98 | 374.5K | 25,000 | — | ↗ |
| 2018-03-01 | Leuthner Brian A | Director / Officer | A-Award | A | Stock Option (Right To Purchase) | 280,000 | 14.98 | 4.19M | 280,000 | — | ↗ |
| 2018-03-01 | Faleck Herbert J | Officer | A-Award | A | Stock Option (Right To Purchase) | 90,000 | 14.98 | 1.35M | 90,000 | — | ↗ |
| 2018-03-01 | BRENNAN DANIEL | Officer | A-Award | A | Stock Option (Right To Purchase) | 90,000 | 14.98 | 1.35M | 90,000 | — | ↗ |
| 2018-02-23 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 15.37 | 38.4K | 75,236 | — | ↗ |
| 2018-02-22 | Macdonald R. Loch | Director / Officer | S-Sale | D | Common Stock | 2,500 | 14.49 | 36.2K | 583,102 | — | ↗ |
| 2018-02-22 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 15.47 | 38.7K | 77,736 | — | ↗ |
| 2018-02-21 | Macdonald R. Loch | Director / Officer | S-Sale | D | Common Stock | 5,000 | 13.82 | 69.1K | 585,602 | — | ↗ |
| 2018-02-20 | Macdonald R. Loch | Director / Officer | S-Sale | D | Common Stock | 5,000 | 13.75 | 68.8K | 590,602 | — | ↗ |
| 2018-02-02 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 12.96 | 32.4K | 80,236 | — | ↗ |
| 2018-02-01 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 13.14 | 32.9K | 82,736 | — | ↗ |
| 2018-01-03 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.11 | 25.3K | 85,236 | — | ↗ |
| 2018-01-02 | MARCHIO ALBERT N II | Officer | A-Award | A | Stock Option (Right To Purchase) | 50,000 | 10.10 | 505.0K | 50,000 | — | ↗ |
| 2018-01-02 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.11 | 25.3K | 87,736 | — | ↗ |
| 2018-01-02 | Faleck Herbert J | Officer | A-Award | A | Stock Option (Right To Purchase) | 50,000 | 10.10 | 505.0K | 50,000 | — | ↗ |
| 2017-12-05 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 9.68 | 24.2K | 90,236 | — | ↗ |
| 2017-12-04 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 9.97 | 24.9K | 92,736 | — | ↗ |
| 2017-12-01 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 9.92 | 24.8K | 95,236 | — | ↗ |
| 2017-11-22 | MARCHIO ALBERT N II | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-03 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.86 | 27.2K | 97,736 | — | ↗ |
| 2017-11-02 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.94 | 27.4K | 100,236 | — | ↗ |
| 2017-11-01 | Saik Andrew | Officer | A-Award | A | Stock Option (Right To Purchase) | 200,000 | 10.73 | 2.15M | 200,000 | — | ↗ |
| 2017-11-01 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.92 | 27.3K | 102,736 | — | ↗ |
| 2017-10-31 | Saik Andrew | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-10-04 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 11.14 | 27.9K | 105,236 | — | ↗ |
| 2017-10-03 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.93 | 27.3K | 107,736 | — | ↗ |
| 2017-10-02 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.81 | 27.0K | 110,236 | — | ↗ |
| 2017-09-18 | Crane Rosemary A | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-09-06 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.31 | 25.8K | 112,736 | — | ↗ |
| 2017-09-05 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 9.94 | 24.9K | 115,236 | — | ↗ |
| 2017-09-01 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.37 | 25.9K | 117,736 | — | ↗ |
| 2017-08-29 | MARCHIO ALBERT N II | Officer | S-Sale | D | Common Stock | 2,500 | 10.42 | 26.1K | 3,361 | — | ↗ |
| 2017-08-23 | MARCHIO ALBERT N II | Officer | S-Sale | D | Common Stock | 1,000 | 10.39 | 10.4K | 5,861 | — | ↗ |
| 2017-08-03 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.40 | 26.0K | 120,236 | — | ↗ |
| 2017-08-02 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.53 | 26.3K | 122,736 | — | ↗ |
| 2017-08-01 | Leuthner Brian A | Director / Officer | S-Sale | D | Common Stock | 2,500 | 10.65 | 26.6K | 125,236 | — | ↗ |
| 2017-07-07 | BARER SOL J | Director | X-InTheMoney | D | Warrants (right To Purchase) | 12,530 | 2.39 | 29.9K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
55.82M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2019 | Frank Bedu-Addo, Ph.D. Chief Executive Officer | 356.3K | 395.0K | — | 1.83M | — | — | 2.58M | 70.92% | ↗ |
| 2 | 2019 | Brian A. Leuthner Former Chief Executive Officer | 110.4K | — | — | — | — | 896.6K | 1.01M | 0.00% | ↗ |
| 3 | 2019 | Andrew Saik Former Chief Financial Officer | 370.0K | — | — | 309.4K | — | — | 679.4K | 45.54% | ↗ |
| 4 | 2019 | Gregory L. Conn, Ph.D. Chief Scientific Officer | 169.2K | — | — | 461.6K | — | 38.2K | 669.0K | 69.00% | ↗ |
| 5 | 2019 | W. Bradford Middlekauff Former SVP, General Counsel and Secretary | 121.7K | 156.4K | — | — | — | — | 278.1K | 0.00% | ↗ |
| 6 | 2018 | Brian A. Leuthner Former Chief Executive Officer | 530.0K | 318.0K | 143.8K | 3.36M | — | 10.8K | 4.36M | 80.30% | ↗ |
| 7 | 2018 | Brian A. Leuthner Chief Executive Officer | 530.0K | 318.0K | — | 3.36M | — | 7.5K | 4.36M | 77.06% | ↗ |
| 8 | 2018 | W. Bradford Middlekauff Former SVP, General Counsel and Secretary | 347.7K | 157.5K | 42.4K | 791.4K | — | 11.0K | 1.35M | 61.76% | ↗ |
| 9 | 2018 | W. Bradford Middlekauff SVP, General Counsel and Secretary | 347.7K | 157.5K | — | 791.4K | — | 11.0K | 1.35M | 58.63% | ↗ |
| 10 | 2018 | Herbert J. Faleck Chief Medical Officer | 416.0K | 187.2K | — | 646.9K | — | 11.0K | 1.31M | 49.31% | ↗ |
| 11 | 2018 | Andrew Saik Former Chief Financial Officer | 370.0K | 166.5K | 70.6K | 660.5K | — | — | 1.27M | 57.68% | ↗ |
| 12 | 2018 | Andrew Saik Chief Financial Officer | 370.0K | 166.5K | — | 660.5K | — | — | 1.27M | 52.10% | ↗ |
| 13 | 2018 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Officer | 150.8K | — | — | 11.6K | — | 272.2K | 443.0K | 2.61% | ↗ |
| 14 | 2018 | Gregory L. Conn, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 15 | 2018 | Frank Bedu-Addo, Ph.D. Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 16 | 2017 | Brian A. Leuthner President and Chief Executive Officer | 500.0K | — | — | 1.76M | 255.0K | 10.8K | 2.53M | 69.70% | ↗ |
| 17 | 2017 | Brian A. Leuthner Chief Executive Officer | 500.0K | 255.0K | — | 1.76M | — | 10.8K | 2.53M | 69.70% | ↗ |
| 18 | 2017 | Andrew Saik Chief Financial Officer | 61.7K | — | — | 1.59M | — | — | 1.66M | 96.28% | ↗ |
| 19 | 2017 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Officer | 402.0K | 153.8K | — | 724.5K | — | 10.8K | 1.29M | 56.12% | ↗ |
| 20 | 2017 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Officer | 402.0K | — | — | 724.5K | 153.8K | 10.8K | 1.29M | 56.12% | ↗ |
| 21 | 2017 | Herbert J. Faleck Chief Medical Officer | 400.0K | 153.0K | — | 724.5K | — | 10.8K | 1.29M | 56.24% | ↗ |
| 22 | 2017 | Herbert J. Faleck, D.O. Chief Medical Officer | 400.0K | — | — | 724.5K | 153.0K | 10.8K | 1.29M | 56.24% | ↗ |
| 23 | 2017 | W. Bradford Middlekauff SVP, General Counsel and Secretary | 328.0K | 97.6K | — | 345.8K | — | 10.8K | 782.2K | 44.21% | ↗ |
| 24 | 2016 | Brian A. Leuthner President and Chief Executive Offıcer | 467.5K | — | — | 1.11M | 266.5K | — | 1.84M | 60.13% | ↗ |
| 25 | 2016 | Brian A. Leuthner President and Chief Executive Officer | 467.5K | — | — | 1.11M | 266.5K | — | 1.84M | 60.13% | ↗ |
| 26 | 2016 | Herbert J. Faleck, D.O. Chief Medical Officer | 377.1K | — | — | 653.9K | 169.7K | — | 1.20M | 54.46% | ↗ |
| 27 | 2016 | Herbert J. Faleck, D.O. Chief Medical Offıcer | 337.1K | — | — | 653.9K | 150.8K | — | 1.14M | 57.27% | ↗ |
| 28 | 2016 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Officer | 390.0K | — | — | 409.0K | 175.5K | — | 974.5K | 41.97% | ↗ |
| 29 | 2016 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Offıcer | 390.0K | — | — | 409.0K | 175.5K | — | 974.5K | 41.97% | ↗ |
| 30 | 2015 | Brian A. Leuthner President and Chief Executive Officer | 376.3K | 268.6K | — | 2.23M | — | — | 2.87M | 77.54% | ↗ |
| 31 | 2015 | Brian A. Leuthner President and Chief Executive Offıcer | 376.3K | — | — | 2.23M | 268.6K | — | 2.87M | 77.54% | ↗ |
| 32 | 2015 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Officer | 311.3K | 166.7K | — | 2.07M | — | — | 2.54M | 81.22% | ↗ |
| 33 | 2015 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Offıcer | 311.3K | — | — | 2.07M | 166.7K | — | 2.54M | 81.22% | ↗ |
| 34 | 2015 | Herbert J. Faleck, D.O. Chief Medical Officer | 311.3K | 148.2K | — | 494.7K | — | — | 954.1K | 51.85% | ↗ |
| 35 | 2015 | Herbert J. Faleck, D.O. Chief Medical Offıcer | 311.3K | — | — | 494.7K | 148.2K | — | 945.1K | 52.35% | ↗ |
| 36 | 2014 | Herbert J. Faleck, D.O. Chief Medical Officer | 280.0K | 79.8K | — | 785.0K | — | — | 1.14M | 68.57% | ↗ |
| 37 | 2014 | Brian A. Leuthner President and Chief Executive Officer | 330.0K | 141.1K | — | 366.2K | — | — | 837.2K | 43.73% | ↗ |
| 38 | 2014 | R. Loch Macdonald, M.D., Ph.D. Chief Scientific Officer | 275.0K | 78.4K | — | 337.2K | — | — | 690.6K | 48.83% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Frank K. Bedu-Addo | President, Chief Executive Officer & Director | 634.8K | — |
| Kirk V. Shepard | Chief Medical Officer | 483.8K | — |
| Stephan Toutain | Chief Operating Officer | 480.1K | male |
| Gregory L. Conn | Chief Scientific Officer | 194.7K | — |
| Janetta Trochimiuk | Controller | — | female |
| Lars Robert Boesgaard | Principal Financial & Accounting Officer and Chief Financial Officer | — | male |
| Spencer Brown | Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PDSB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
